STAT+: Pharmalittle: Chinese authorities summon AstraZeneca execs over insurance fraud; Lilly to invest $1.5B in two factories

Good morning, everyone, and welcome to another working week. We hope the weekend respite was somehow invigorating and relaxing, despite the storm that battered some parts. As for us, we successfully returned from depositing our shortest person at an institution of higher learning just in time to retrieve our shovel from the tool shed. And so, we will celebrate with a well-earned cup or three of stimulation. Our choice today is stroopwafel. Yes, this is a real thing. So feel free to join us. Meanwhile, we have assembled another lineup of interesting items to hopefully jumpstart your day. Hope all goes well and, as always, do keep in touch. We enjoy your postcards and telegrams …
The market for biotech talent in Massachusetts has long been robust, but lately the crunch has turned critical, as the pipeline of qualified workers to fill all of the added jobs can’t keep up with the burgeoning demand , The Boston Globe writes. And this is causing some in the industry to worry that it will not only inhibit growth, but also affect the quality of work as key positions become harder to fill and lower-level workers jump from company to company in search of a better compensation package. Employee turnover is on the rise, too. About 16.5% of life sciences employees in Massachusetts voluntarily quit their jobs last year, up from 13% in 2018. Continue to STAT+ to read the full story…